Cardiovascular Protective Effect of Spironolactone in Hemodialysis
Recruitment status was Recruiting
The purpose of the present study is to determine if spironolactone is safe and effective in the treatment of cardiovascular complications in hemodialysis patients.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies|
Cardiovascular complications are common in dialysis patients and comprise up to 50% of deaths in end-stage renal disease population. Hypertension and left ventricle hypertrophy occur in more than 70% of patients undergoing long-term hemodialysis therapy, and both contributes to mortality and morbidity.Recent clinical trials in chronic heart failure and post miocardial infarct heart failure patients have demonstrated a beneficial effect of a mineralocorticoid receptor blocker spironolactone, in adittion to standard therapy (RALES AND EPHESUS studies). The aim of the present study is to evaluate spironolactone treatment in hemodialysis patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00277693
|Contact: Antonio Vukusich, MDfirstname.lastname@example.org|
|Contact: Antonio Vukusich, MD 56-2-7308021 email@example.com|
|Contact: Elisa T Marusic, PhD 56-2-4129341 firstname.lastname@example.org|
|Principal Investigator: Antonio Vukusich, MD|
|Study Chair:||Luis F Michea, MD PhD||Faculty of Medicine, University Los Andes|